NCT02721459View on ClinicalTrials.gov

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 7, 2016

Primary Completion Date

October 31, 2019

Study Completion Date

November 30, 2025

Conditions
MelanomaSkin Cancer
Interventions
DRUG

XL888

"Level 1: XL888 30 mg by mouth (PO) twice weekly (BIW). Level 2: XL888 45 mg PO BIW.~Level 3: XL888 60 mg PO BIW. Level 4: XL888 90 mg PO BIW."

DRUG

Vemurafenib

Vemurafenib 720 mg by mouth twice a day (BID)

DRUG

Cobimetinib

Cobimetinib 40 mg by mouth once daily (QD). Administered 3 weeks on, 1 week off.

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

Sponsors

Collaborators (2)

Exelixis
Genentech, Inc.
All Listed Sponsors
collaborator

Exelixis

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER